FAP and osteoarthritis: The complex of FAP with its endogenous inhibitor OLN, which impacts the outcomes of bone diseases such as osteoarthritis, was predicted by AlphaFold3 (Figure S2, Supporting Information) and validated through co‐immunoprecipitation assays.[14] Subsequently, we assessed the expression of FAP and its endogenous inhibitor OLN in gingival tissue specimens from healthy individuals and patients with periodontitis.